Global Insulin Market Witnesses a Key Approval by FDA

Published By : 21 Dec 2015 |Published By : QYRESEARCH

Basaglar, an insulin glargine injection was finally approved by the U.S. Food and Drug Administration. This long-acting human insulin analog is intended to enhance the glycemic control for both type 1 and 2 diabetic patients.

About 21 Million Diabetics Diagnosed Each Year

The Centers for Disease Control and Prevention stated that about 21 million people are diagnosed with diabetes with each passing year. With time, these patients live with a risk of falling a prey to serious health conditions such as cardiovascular diseases, kidney and nerve damage, and other several other complications. Therefore, if the blood sugar is controlled for a longer period, this risk can be mitigated and the chances of complications reduced.

Global Insulin Market to Grow due to Rising Research and Development

With increasing research and development for management of diabetes and growing investments made by the medical fraternity, governments, and private sector to develop drugs for the disease, the global insulin market has received a serious impetus in the recent years. The global insulin market’s growth will be centered about increasing number of people suffering from diabetes and large part of the treatment being based on trial and error.

Approval of Long-acting Insulin Glargine Offers Major Relief to Patients

The approval of long-acting insulin products such as glargine comes as a huge relief to both medical practitioners and a patients. This type of insulin will change the face of the global insulin market as it will play an important role in treating type 1 and 2 diabetes.

Failure for Remedying Diabetes to Propel Growth of Insulin Market

The failure of researchers to not find a cure for this deadly condition is the largely the reason for the accelerating consumption of insulin. However, the quest for an ingenious solution for remedying this disease is expected to keep the spirit of the global insulin market high. The inadequacy of a solution and a need to save lives still makes insulin therapy an indispensable for patients suffering with type-1 diabetes.